When does the weight loss plateau occur on drugs like Ozempic, and can you delay it?

Health & Lifestyle
185

Listen to article (english)

Translate to Spanish or other 102 languages!

When is a person likely to reach a weight loss plateau on GLP-1 agonists vs surgery vs dietary interventions? Image for illustration purposes
When is a person likely to reach a weight loss plateau on GLP-1 agonists vs surgery vs dietary interventions? Image for illustration purposes

Medical News Today

- Advertisement -
  • A new study investigated why different obesity treatments, including diets, surgeries and new medications like GLP-1 receptor agonists, such as semaglutide and tirzepatide, lead to varying times at which weight loss plateaus.
  • Utilizing a mathematical model, the research examines how these interventions alter the body’s regulation of energy intake and expenditure, affecting the duration of effective weight loss.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/when-does-the-loss-plateau-occur-on-drugs-like-ozempic-and-can-you-delay-it

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Vaccines for Family & Caregivers 
Next article
Weight-Loss Surgery Before Kidney Transplantation Improves Health & Eligibility of Patients with Obesity & Renal Failure

More Articles

Beat the Summer Heat: Essential Hydration Tips

Summer heat has a way of sneaking up on you, making it easy to become dehydrated before you even realize you're thirsty.

STHS’ Transform Your Life Event Inspires Healthier Living Across the RGV

Whether you're making healthier food choices, becoming more active or focusing on your mental well-being, every positive change can help you live a longer, healthier and more fulfilling life.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

Physicians Warn of Rising ER Visits Linked to E-Bikes and Scooters

Mega Doctor News CLEVELAND CLINIC - As electric bikes and scooters grow in...
- Advertisement -